Viridium Pacific (TSXV:VIR) CEO Jay Garnett recently conducted an interview with Green Chip Stocks Editor Jeff Siegel regarding the company’s progress in clinical research studies related to cannabis.
According to Garnett, Viridium (which is soon to be called Experion) has sponsored one of the first Phase II and Phase III clinical research studies related to post-operative pain reduction. The study is one of the most advanced cannabis-related research projects in all of Canada. Viridium began generating revenue in September 2018 through its wholesale flower business, which has developed a reputation for high-quality products and sales service.
“We started with wholesale flower and quickly established a reputation for high-quality product and sales service. Our regular customers include Emerald Therapeutics, Tilray, High Point, to name a few. We have now entered into the Adult Use market with several Canadian provincial distributors. Whilst Experion was not the first to market, we were one of the fastest products to sell out with increased re-orders across the board,” said Jay Garnett, CEO of Viridium Pacific.
Garnett also went on to explain Viridium’s business strategy, which is aimed at generating multiple revenue streams and business opportunities. The company has established a strong reputation in B2B sales, offering clones to other licensed producers looking to establish their cultivation operations.
To read more of the conversation between Garnett and Siegel, click here.
Both locations expand access to the state’s widest-ranging inventory of medical cannabis products for Central Florida patients
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of two brand-new Central Florida dispensaries. The new Clearwater and Tampa locations mark the Company’s 81 st and 82 nd nationwide, respectively, widening patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Philip Young, CEO and Director of Lobe, stated, “We are honored to welcome Bart to our Advisory Board. His first-hand experience on and off the field are tremendously valuable as we continue our research involving mild traumatic brain injuries and PTSD. These issues are prevalent in contact sports and we believe that athletes will play a prominent role in the continued acceptance of psychedelic medicines as legitimate treatment. We look forward to working with Bart as we seek to forge long-term strategic relationships.”
HempFusion Wellness Submits Novel Foods Dossier to the United Kingdom’s Regulatory Food Safety Agency
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that it has submitted its dossier to the United Kingdom’s Regulatory Food Safety Agency (the “FSA”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005322/en/